McKesson(MCK) - 2026 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported consolidated revenues of $106.2 billion, an increase of 11% year-over-year, driven by broad-based growth across the business [21][28] - Adjusted earnings per diluted share increased 16% to $9.34, reflecting strong operational performance [22][28] - Operating profit rose 13% year-over-year to $1.7 billion, supported by increased demand for access solutions and strong growth in specialty distribution [22][28] Business Line Data and Key Metrics Changes - North American pharmaceutical revenues increased by 9% to $88.3 billion, driven by higher prescription volumes and specialty product distribution strength [23][28] - Oncology and multispecialty segment revenues surged by 37% to $13 billion, with operating profit increasing by 57% to $366 million, aided by provider growth and acquisitions [24][28] - Prescription technology solutions revenues grew by 9% to $1.5 billion, with operating profit rising 18% to $277 million, driven by demand for access solutions [25][28] - Medical-surgical solutions revenues increased by 1% to $3 billion, but operating profit decreased by 10% to $265 million due to lower volumes [25][28] Market Data and Key Metrics Changes - GLP-1 distribution revenues reached $14 billion, up $3 billion or 26% compared to the prior year, indicating strong demand in the market [23][28] - The company continues to see stable utilization trends and strong specialty distribution growth across its North American pharmaceutical segment [29][30] Company Strategy and Development Direction - The company is focused on two strategic growth pillars: oncology and multispecialty, and biopharma services, leveraging its scale and leadership to meet evolving market needs [7][8] - Investments are being made in technology and automation to enhance operational efficiency and improve patient access to medications [11][12] - The company is progressing with the separation of its medical-surgical business, aiming for an IPO by the second half of calendar 2027 [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to extend momentum and execute against strategic priorities, raising full-year EPS guidance to a range of $38.80-$39.20, reflecting 17%-19% growth [5][28] - The company anticipates revenue growth of 12%-16% and operating profit growth of 13%-17% for the full year, supported by strong third-quarter performance [28][29] - Management highlighted the importance of community-based care and the role of advocacy in expanding patient access [9][10] Other Important Information - The company completed the divestiture of its Norwegian operations, marking the final step in its exit from Europe, which is expected to contribute approximately $1 billion in revenue for fiscal 2026 [20][28] - Free cash flow for the quarter was $1.1 billion, with a total of $9.6 billion for the trailing 12 months, demonstrating strong operational performance [26][27] Q&A Session Summary Question: Can you discuss the specific investments in technology and automation? - Management highlighted investments in AI and automation to improve workflows, resulting in increased productivity during the annual verification season [38][39] Question: What are the long-term opportunities for margin improvement in the segment? - Management noted that half of the segment's revenue is related to third-party logistics, with ongoing automation expected to improve margins [43][44] Question: Any nuances to consider for fiscal 2027 guidance? - Management indicated stable utilization trends and strong specialty distribution growth, with operational efficiency gains supporting positive growth [48][50] Question: What is driving the margin improvement in oncology and multispecialty? - Management attributed margin improvements to provider additions and continued growth in specialty oncology products [55][57] Question: How is the company navigating the regulatory environment? - Management expressed confidence in navigating the regulatory landscape, emphasizing constructive conversations with manufacturing partners [66][69]